Compile Data Set for Download or QSAR
maximum 50k data
Found 191 with Last Name = 'hamaguchi' and Initial = 'w'
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148155(US8962612, 26)
Affinity DataKi:  0.680nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148163(US8962612, 66)
Affinity DataKi:  0.75nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148169(US8962612, 80)
Affinity DataKi:  0.850nM ΔG°:  -53.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148165(US8962612, 74)
Affinity DataKi:  0.880nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148171(US8962612, 86)
Affinity DataKi:  0.950nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148156(US8962612, 28)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148154(US8962612, 23)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135790(US8853242, 162)
Affinity DataKi:  1.20nM ΔG°:  -50.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135785(US8853242, 152)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135780(US8853242, 60)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148167(US8962612, 78)
Affinity DataKi:  1.30nM ΔG°:  -52.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135783(US8853242, 148)
Affinity DataKi:  1.40nM ΔG°:  -50.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148164(US8962612, 69)
Affinity DataKi:  1.60nM ΔG°:  -52.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135782(US8853242, 147)
Affinity DataKi:  1.60nM ΔG°:  -50.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135795(US8853242, 192)
Affinity DataKi:  1.80nM ΔG°:  -49.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135792(US8853242, 170)
Affinity DataKi:  1.90nM ΔG°:  -49.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148162(US8962612, 62)
Affinity DataKi:  1.90nM ΔG°:  -51.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135796(US8853242, 211)
Affinity DataKi:  2.30nM ΔG°:  -49.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148161(US8962612, 61)
Affinity DataKi:  2.5nM ΔG°:  -51.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148166(US8962612, 76)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148157(US8962612, 44)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135788(US8853242, 160)
Affinity DataKi:  3.30nM ΔG°:  -48.4kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135789(US8853242, 161)
Affinity DataKi:  3.40nM ΔG°:  -48.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148153(US8962612, 8)
Affinity DataKi:  3.60nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148168(US8962612, 79)
Affinity DataKi:  3.70nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135781(US8853242, 114)
Affinity DataKi:  3.70nM ΔG°:  -48.1kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148160(US8962612, 60)
Affinity DataKi:  3.90nM ΔG°:  -49.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135784(US8853242, 151)
Affinity DataKi:  4.10nM ΔG°:  -47.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148170(US8962612, 81)
Affinity DataKi:  4.20nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148152(US8962612, 4)
Affinity DataKi:  4.30nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135794(US8853242, 187)
Affinity DataKi:  4.60nM ΔG°:  -47.6kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135791(US8853242, 164)
Affinity DataKi:  4.70nM ΔG°:  -47.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135786(US8853242, 157)
Affinity DataKi:  5.30nM ΔG°:  -47.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135793(US8853242, 171)
Affinity DataKi:  6.20nM ΔG°:  -46.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148159(US8962612, 49)
Affinity DataKi:  6.60nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148158(US8962612, 46)
Affinity DataKi:  6.90nM ΔG°:  -48.5kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135787(US8853242, 159)
Affinity DataKi:  7.10nM ΔG°:  -46.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135779(US8853242, 6)
Affinity DataKi:  13nM ΔG°:  -45.0kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50520336(CHEMBL4470042)
Affinity DataIC50:  2nMAssay Description:Inhibition of human PDE10A using cAMP as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by HTRF detecti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50521882(CHEMBL4469155)
Affinity DataIC50:  2.90nMAssay Description:Inhibition of human PDE10A using cAMP as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by HTRF detecti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50521887(CHEMBL4459939)
Affinity DataIC50:  8.40nMAssay Description:Inhibition of human PDE10A using cAMP as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by HTRF detecti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium- and chloride-dependent glycine transporter 1(attus norvegicus (Rat))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50149871((R)-2-((3-(biphenyl-4-yloxy)-3-(4-fluorophenyl)pro...)
Affinity DataIC50:  8.90nMAssay Description:Displacement of [3H]glycine from GlyT1 in rat C6 glioma cells incubated for 30 mins prior to substrate addition measured after 10 mins by scintillati...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50243945(2-(1,4'-Bipiperidine-1'-yl)-N-cycloheptyl-6,7-dime...)
Affinity DataIC50:  18nMAssay Description:Antagonist activity at human CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50265669((1'-{4-[(4-Chlorophenyl)amino]-6,7-dimethoxyquinaz...)
Affinity DataIC50:  19nMAssay Description:Antagonist activity at human CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced chemotaxisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Mus musculus)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50265742(CHEMBL521737 | {1'-[4-(Cycloheptylamino)-6,7-dimet...)
Affinity DataIC50:  19nMAssay Description:Antagonist activity at mouse CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced chemotaxisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50244380(CHEMBL487635 | N-Cycloheptyl-6,7-dimethoxy-2-(4-py...)
Affinity DataIC50:  19nMAssay Description:Antagonist activity at human CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium- and chloride-dependent glycine transporter 1(attus norvegicus (Rat))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50102692(4-Benzyloxy-N-(1-dimethylamino-cyclopentylmethyl)-...)
Affinity DataIC50:  22nMAssay Description:Displacement of [3H]glycine from GlyT1 in rat C6 glioma cells incubated for 30 mins prior to substrate addition measured after 10 mins by scintillati...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50265669((1'-{4-[(4-Chlorophenyl)amino]-6,7-dimethoxyquinaz...)
Affinity DataIC50:  23nMAssay Description:Antagonist activity at human CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced chemotaxisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 4(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50245036(CHEMBL486840 | N-(4-Chlorophenyl)-6,7-dimethoxy-2-...)
Affinity DataIC50:  24nMAssay Description:Antagonist activity at human CCR4 receptor expressed in mouse B300-19 cells assessed as CCL22-induced chemotaxisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50521879(CHEMBL4559232)
Affinity DataIC50:  28nMAssay Description:Inhibition of human PDE10A using cAMP as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by HTRF detecti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
Displayed 1 to 50 (of 191 total ) | Next | Last >>
Jump to: